{"nctId":"NCT01732796","briefTitle":"IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1","startDateStruct":{"date":"2012-12"},"conditions":["Hepatitis C, Chronic"],"count":470,"armGroups":[{"label":"Allocated 24 weeks BI 207127 + BI 201335","type":"EXPERIMENTAL","interventionNames":["Drug: Ribavirin (RBV)","Drug: BI 201335 (Faldaprevir)","Drug: BI 207127"]},{"label":"Randomized 16 weeks BI 7127+BI1335 + RBV","type":"EXPERIMENTAL","interventionNames":["Drug: BI 201335 (Faldaprevir)","Drug: Ribavirin (RBV)","Drug: BI 207127"]},{"label":"Randomized 24weeks BI 7127+ BI1335 + RBV","type":"EXPERIMENTAL","interventionNames":["Drug: Ribavirin (RBV)","Drug: BI 207127","Drug: Faldaprevir (BI 201335)"]}],"interventions":[{"name":"Ribavirin (RBV)","otherNames":[]},{"name":"BI 201335 (Faldaprevir)","otherNames":[]},{"name":"Ribavirin (RBV)","otherNames":[]},{"name":"BI 207127","otherNames":[]},{"name":"BI 201335 (Faldaprevir)","otherNames":[]},{"name":"Ribavirin (RBV)","otherNames":[]},{"name":"BI 207127","otherNames":[]},{"name":"Faldaprevir (BI 201335)","otherNames":[]},{"name":"BI 207127","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Chronic hepatitis C infection, diagnosed by positive HCV Ab or detectable HCV RNA at screening in addition to at least one of the following:\n\n  1. positive HCV RNA or HCV antibodies at least 6 months prior to screening, or\n  2. liver biopsy typical of chronic hepatitis C , or\n  3. history of elevated ALT at least 6 months prior to screening.\n* HCV infection of sub-GT1b confirmed by genotypic testing at screening\n* Treatment naÃ¯ve defined as:\n\n  1. no prior treatment with any interferon, pegylated interferon, and /or ribavirin and\n  2. no prior treatment with at least one dose of any other licensed or investigational antiviral agent for acute or chronic hepatitis C infection\n* Plasma HCV RNA \\> or = 1,000 IU/mL at screening\n* Liver biopsy within three years or fibroscan within six months prior to randomization. Patients with compensated liver cirrhosis (score Child-Pugh A) could also be included.\n* Age 18 to 75 years\n* Female patients with a negative urine pregnancy test (dipstick) at Visit 2 prior to randomization\n\n  1. with documented hysterectomy, or\n  2. who have had both ovaries removed, or\n  3. with documented tubal ligation, or\n  4. who are post-menopausal with last menstrual period at least 12 months prior to screening, or\n  5. of childbearing potential with a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (Visit 2), that agree to use two non-hormonal methods of birth control from the date of screening until months after the last dose of ribavirin. They must not breast-feed at any time from the date of screening until 7 months after the last dose of ribavirin. Medically accepted methods of contraception for females in this trial are diaphragm with spermicide substance, intrauterine devices, cervical caps and condoms.\n\nOR:\n\nMale patients\n\n1. who are documented to be sterile, or\n2. who consistently and correctly use a condom while their female partners (if of child-bearing potential) agree to use one of the appropriate medically accepted methods of birth control from the date of screening until 7 months after the last dose of ribavirin, and\n3. without pregnant female partners. It is in the responsibility of the male patient to ensure that his partner (or partners) is not pregnant prior to enrolment into the study or becomes pregnant during the treatment and follow-up phase. Female partners of childbearing potential must perform monthly pregnancy tests from the date of screening until 7 months after the last dose of ribavirin (tests will be provided by the sponsor).\n\nExclusion criteria:\n\n* HCV infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening.\n* HCV subtype 1a, mixed 1a/1b or GT1 undefined\n* Evidence of liver disease mainly due to causes other than chronic HCV infection such as autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis or Wilson's disease\n* HIV-1 or HIV-2 infection\n* Hepatitis B virus (HBV) infection based on presence of HBs-Ag\n* Evidence of decompensated liver disease, or history of decompensated liver disease, defined as history of ascites, hepatic encephalopathy, or bleeding esophageal varices,\n* International Normalized Ratio (INR) \\> or =1.7\n* Serum albumin \\< 3.3 g/dL\n* Serum total bilirubin \\>2.0 times the upper limit of normal (ULN) with direct/indirect ratio \\>1, unless history of Gilbert's disease\n* Active or suspected malignancy or history of malignancy within the last 5 years (with the exception of appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)\n* Patients with ongoing or historical photosensitivity or recurrent rash","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SVR12 Rates With Historical Control","description":"Sustained Virologic Response at Week 12 post-treatment (SVR12): Plasma Hepatitis C Virus ribonucleic acid (HCV RNA) level \\<25 international units/millilitre (IU/mL) at 12 weeks after End of Treatment (EoT). SVR12, was assessed based on the observed HCV RNA result taken at least 10 weeks after treatment discontinuation. This definition was also applied to patients who discontinued treatment early: if the patient had HCV RNA undetected at least 10 weeks after stopping all treatment, they were considered a responder in the primary analysis. This is the primary analyses of the primary endpoint","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"71.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":null},{"groupId":"OG001","value":"72.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Comparisons of SVR12 Rates Across Treatment Arms","description":"Sustained Virologic Response rates across treatment arms at Week 12 post-treatment (SVR12). This is the secondary analyses of the primary endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"82.5","spread":null},{"groupId":"OG002","value":"72.5","spread":null}]}]}]},{"type":"SECONDARY","title":"SVR4","description":"Sustained Virologic Response rates across treatment arms at Week 4 post-treatment (SVR4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.4","spread":null},{"groupId":"OG001","value":"84.4","spread":null},{"groupId":"OG002","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"95.0","spread":null}]}]}]},{"type":"SECONDARY","title":"SVR24","description":"Sustained Virologic Response rates across treatment arms at Week 24 post-treatment (SVR24).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null},{"groupId":"OG001","value":"80.6","spread":null},{"groupId":"OG002","value":"72.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"99.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":208},"commonTop":["Nausea","Vomiting","Diarrhoea","Fatigue","Anaemia"]}}}